Acorah Software Products - Accounts Production 19.2.450 false true 31 March 2025 1 April 2024 false 1 April 2025 31 March 2026 31 March 2026 09499319 Mr D W Keogh Mrs J M Keogh iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09499319 2025-03-31 09499319 2026-03-31 09499319 2025-04-01 2026-03-31 09499319 frs-core:CurrentFinancialInstruments 2026-03-31 09499319 frs-core:Non-currentFinancialInstruments 2026-03-31 09499319 frs-core:ComputerEquipment 2025-04-01 2026-03-31 09499319 frs-core:PlantMachinery 2026-03-31 09499319 frs-core:PlantMachinery 2025-04-01 2026-03-31 09499319 frs-core:PlantMachinery 2025-03-31 09499319 frs-core:ShareCapital 2026-03-31 09499319 frs-core:RetainedEarningsAccumulatedLosses 2026-03-31 09499319 frs-bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 09499319 frs-bus:FilletedAccounts 2025-04-01 2026-03-31 09499319 frs-bus:SmallEntities 2025-04-01 2026-03-31 09499319 frs-bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 09499319 frs-bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 09499319 frs-core:UnlistedNon-exchangeTraded 2026-03-31 09499319 frs-core:UnlistedNon-exchangeTraded 2025-03-31 09499319 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-03-31 09499319 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2026-03-31 09499319 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-03-31 09499319 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2026-03-31 09499319 frs-bus:Director1 2025-04-01 2026-03-31 09499319 frs-bus:Director2 2025-04-01 2026-03-31 09499319 frs-countries:EnglandWales 2025-04-01 2026-03-31 09499319 2024-03-31 09499319 2025-03-31 09499319 2024-04-01 2025-03-31 09499319 frs-core:CurrentFinancialInstruments 2025-03-31 09499319 frs-core:Non-currentFinancialInstruments 2025-03-31 09499319 frs-core:ShareCapital 2025-03-31 09499319 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31
Registered number: 09499319
Medeyecare Limited
Unaudited Financial Statements
For The Year Ended 31 March 2026
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 09499319
2026 2025
Notes £ £ £ £
FIXED ASSETS
Investments 5 391,600 391,600
391,600 391,600
CURRENT ASSETS
Cash at bank and in hand 605 1,124
605 1,124
Creditors: Amounts Falling Due Within One Year 6 (9,412 ) (35,904 )
NET CURRENT ASSETS (LIABILITIES) (8,807 ) (34,780 )
TOTAL ASSETS LESS CURRENT LIABILITIES 382,793 356,820
Creditors: Amounts Falling Due After More Than One Year 7 (24,339 ) (35,366 )
NET ASSETS 358,454 321,454
CAPITAL AND RESERVES
Called up share capital 9 2 2
Profit and Loss Account 358,452 321,452
SHAREHOLDERS' FUNDS 358,454 321,454
Page 1
Page 2
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr D W Keogh
Director
14 May 2026
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Medeyecare Limited is a private company, limited by shares, incorporated in England & Wales, registered number 09499319 . The registered office is Nestledown, Penhill, Colesbourne, Gloucestershire, GL53 9NS.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Plant & Machinery 25% on cost
Computer Equipment 25% on cost
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2025: NIL)
- -
4. Tangible Assets
Plant & Machinery
£
Cost
As at 1 April 2025 2,037
As at 31 March 2026 2,037
Depreciation
As at 1 April 2025 2,037
As at 31 March 2026 2,037
Net Book Value
As at 31 March 2026 -
As at 1 April 2025 -
Page 3
Page 4
5. Investments
Unlisted
£
Cost or Valuation
As at 1 April 2025 391,600
As at 31 March 2026 391,600
Provision
As at 1 April 2025 -
As at 31 March 2026 -
Net Book Value
As at 31 March 2026 391,600
As at 1 April 2025 391,600
Medeyecare Ltd purchased 100% of the shares of Keith Holland and Associates Limited in June 2016.
6. Creditors: Amounts Falling Due Within One Year
2026 2025
£ £
Trade creditors 1 1
Bank loans and overdrafts 8,955 35,200
Other creditors 456 703
9,412 35,904
7. Creditors: Amounts Falling Due After More Than One Year
2026 2025
£ £
Bank loans - 8,955
Amounts owed to subsidiaries 24,339 26,411
24,339 35,366
8. Secured Creditors
Of the creditors the following amounts are secured.
2026 2025
£ £
Bank loans and overdrafts 8,955 44,155
9. Share Capital
2026 2025
£ £
Allotted, Called up and fully paid 2 2
Page 4